TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$100 Million

Coherus Biosciences

At-the-market Offering

Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Biosimilars are an emerging class of protein-based therapeutics with similar physiochemical and structural properties and safety, purity and potency profiles to approved originator products. The Company’s business is organized around four therapeutic franchises which include oncology, immunology (Anti-TNF), ophthalmology and multiple sclerosis small molecule therapeutic candidates. The Company is advancing three late-stage clinical products toward commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etancercept biosimilar) and CHS-1420 (adalimumab biosimilar), and is developing a pipeline of preclinical products.